Thalidomide, Cyclophosphamide and Dexamethasone Induction Therapy: Feasibility for Myeloma Patients Destined for Autologous Stem Cell Transplantation | Citedby Results | Acta Haematologica | Karger Publishers

Skip to Main Content

Skip Nav Destination

Thalidomide, Cyclophosphamide and Dexamethasone Induction Therapy: Feasibility for Myeloma Patients Destined for Autologous Stem Cell Transplantation

Acta Haematol (2014) 132 (2): 226–232.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients

Aneta Szudy-Szczyrek
Radosław Mlak
Michał Szczyrek
Sylwia Chocholska
Jacek Sompor
Adam Nogalski
Teresa Małecka-Massalska
Marek Hus

Oncotarget (2018) 9 (35): 24054.

Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study

Jihyun Kwon
Chang‐Ki Min
Kihyun Kim
Jae‐joon Han
Joon Ho Moon
Hye Jin Kang
Hyeon‐Seok Eom
Min Kyoung Kim
Hyo Jung Kim
Dok Hyun Yoon
Jeong‐Ok Lee
Won Sik Lee
Jae Hoon Lee
Je‐Jung Lee
Yoon‐seok Choi
Sung hyun Kim
Sung‐soo Yoon

Cancer Medicine (2017) 6 (1): 100.

Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy

Raúl Pérez
Mª Sol Durán
Jose Mayans
Alfons Soler
Inmaculada Castillo
Manuel Jurado
Paz Ribas
Mª Carmen Menchaca Echevarria
Miguel T. Hernandez
Mª Dolores Lopez Garcia‐Carreño
Asunción Echeveste Gutierrez
Alicia Bailen Garcia
Silvia Lopez
Jose Baquero
Gemma Ramirez

European Journal of Haematology (2016) 96 (4): 417.

Cyclophosphamides/dexamethasone/thalidomide

Reactions Weekly (2015) 1570 (1): 64.